吡格列酮靶向BCAA/PPAR-γ轴逆转胰岛素抵抗并减轻心脏骤停后损伤
该研究结合回顾性队列(121例CA患者)、前瞻性病例对照(25例CA vs 21例对照)、大鼠CA模型及HT22细胞氧糖剥夺/复氧模型,探讨BCAA代谢紊乱诱导的胰岛素抵抗在心脏骤停后脑损伤中的作用。临床发现CA患者血糖变异度(22.75% vs 14.55%,P<0.0001)和HOMA-IR(4.98 vs 2.62,P=0.001)显著升高且与不良预后相关。大鼠CA后72小时出现全身及脑胰岛素抵抗,海马BCAA蓄积通过抑制PPAR-γ加剧神经炎症和凋亡。吡格列酮激活PPAR-γ可恢复胰岛素敏感性、减轻神经元损伤,使生存率提高40%(P<0.05),神经功能缺损评分改善(66.94 vs 53.78,P<0.001)。
要点
- CA患者血糖变异度(22.75% vs 14.55%,P<0.0001)和HOMA-IR(4.98 vs 2.62,P=0.001)显著升高,与不良预后相关。
- 大鼠CA后72小时出现全身及脑胰岛素抵抗,海马BCAA蓄积由BCKDK上调驱动。
- BCAA通过抑制PPAR-γ通路直接麻痹胰岛素信号,加剧神经炎症和凋亡。
- 吡格列酮激活PPAR-γ可绕过代谢阻滞,使大鼠CA后生存率提高40%(P<0.05)。
- 吡格列酮改善大鼠神经功能缺损评分(66.94 vs 53.78,P<0.001)。
适用人群与场景
- 临床部分纳入121例CA患者(回顾性队列)及25例CA患者与21例对照(前瞻性病例对照),分析代谢指标。
- 动物与细胞实验:大鼠CA模型及HT22细胞氧糖剥夺/复氧模型。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性队列(121例CA患者)、前瞻性病例对照(25例CA vs 21例对照)、大鼠CA模型及HT22细胞氧糖剥夺/复氧模型。
- CA患者血糖变异度显著升高(22.75% vs 14.55%,P<0.0001)且与不良预后相关,HOMA-IR升高(4.98 vs 2.62,P=0.001)。
- 大鼠CA后72小时出现全身及脑胰岛素抵抗,海马BCAA蓄积由BCKDK上调驱动。
- BCAA通过抑制PPAR-γ通路加剧神经炎症和凋亡;吡格列酮激活PPAR-γ恢复胰岛素敏感性、减轻神经元损伤。
- 吡格列酮使大鼠CA后生存率提高40%(P<0.05),神经功能缺损评分改善(66.94 vs 53.78,P<0.001)。
证据类型、等级与局限
- 证据类型:回顾性队列、前瞻性病例对照、动物实验及细胞实验。
- 局限:临床部分为单中心小样本观察性研究,机制验证主要基于大鼠CA模型和HT22细胞,吡格列酮的疗效尚未在CA患者中验证。
对床旁实践的改变
- 该研究提示CA后胰岛素抵抗与BCAA/PPAR-γ轴相关,但吡格列酮的临床疗效尚未在CA患者中证实,不能据此改变当前CA后管理。
- 适用人群:原文未提及吡格列酮在CA患者中的适用人群;不适用人群:原文未提及。
- 常见陷阱:不能将大鼠模型中的生存率提高和神经功能改善直接外推至临床实践。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Metabolic dysfunction contributes to poor outcomes after cardiac arrest (CA). Conventional intensive glucose control fails to improve neurological recovery, and the underlying mechanism remains unclear. We aimed to explore whether insulin resistance (IR) induced by dysregulated branched-chain amino acid (BCAA) metabolism is the core driver of post-CA brain injury, and to verify the therapeutic potential of pioglitazone targeting this pathway.
METHODS: A retrospective cohort (121 CA patients) and a prospective case-control study (25 CA patients vs. 21 controls) were conducted to analyze metabolic indicators. A rat CA model and an HT22 cell oxygen-glucose deprivation/reperfusion model were established. Assessed outcomes included functional neurological outcome, mortality at 30 days, and inflammatory biomarkers levels.
RESULTS: Clinical investigations revealed that CA patients had significantly elevated glucose variability (22.75% vs. 14.55%, P < 0.0001) which correlated with poor prognosis, and elevated homeostasis model assessment of insulin resistance values (4.98 vs. 2.62, P = 0.001). In CA rat model, systemic and cerebral IR developed by 72 h post-resuscitation. Metabolic analysis uncovered a localized BCAA accumulation in the post-CA hippocampus, driven by branched-chain ketoacid dehydrogenase kinase (BCKDK) upregulation. This BCAA directly paralyzed insulin signaling by suppressing the peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway, thereby exacerbating neuroinflammation and apoptosis. Pharmacological activation of PPAR-γ with the FDA-approved agonist pioglitazone bypassed this metabolic blockade, effectively restoring insulin sensitivity, mitigating neuronal injury, and robustly improving post-CA survival (by 40%, P < 0.05) and neurological function (Neurological Deficit Score: 66.94 vs. 53.78, P < 0.001).
CONCLUSIONS: Dysregulated BCAA metabolism triggers IR via PPAR-γ suppression after CA, exacerbating ischemic brain injury. Targeting the BCAA/PPAR-γ/IR axis with pioglitazone effectively reverses this pathology, providing a mechanistically grounded and highly translatable therapeutic strategy for post-resuscitation care.
参考来源
- Sang W, Pan X, Xu F, et al. Targeting BCAA/PPAR-γ axis with pioglitazone reverses insulin resistance and mitigates post-cardiac arrest injury. Resuscitation. 2026. PMID: 42624195. doi:10.1016/j.resuscitation.2026.111272
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。